GlassScriptPhysician profile
Ashleigh B Warren
NPI 1265022776
$598.05
in general payments reported to CMS, 2019-2025
13 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.63 · 2022: $157 · 2023: $64.53 · 2024: $152 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.91 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $86.39 | 2025 | |
| Merck Sharp & Dohme LLC | $53.85 | 2022-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $50.02 | 2022-2024 | Xarelto |
| Cvrx, INC. | $48.70 | 2023-2024 | Barostim Neo System |
| Amgen INC. | $45.58 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $44.67 | 2022-2025 | Ingevity+, Avvigo Guidance System |
| Actelion Pharmaceuticals US, INC. | $43.38 | 2022-2023 | Opsumit, Uptravi |
| Abbott Laboratories | $42.59 | 2024-2025 | Cardiomems |
| Cardiva Medical, INC. | $20.32 | 2025 | Cardiva Vascade 6/7f Vcs |
| Novo Nordisk INC | $19.63 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.91 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.